Work

Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

Year: 2017

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-017-0513-5

Authors: Shumei Kato, Denis L. Jardim, Faye M. Johnson, Vivek Subbiah, Sarina Piha-Paul, Apostolia M. Tsimberidou, Gerald S. Falchook, Daniel Karp, Ralph Zinner, Jennifer Wheler, Filip Janku, Siqing Fu, JoAnn Lim, Stacie Bean, Ly Nguyen, Susan Urban, Elsa Browne, Funda Meric-Bernstam, David S. Hong

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Mechanisms and Therapy

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G111615301, Cancer Center Support Grant

OpenAlex ID: W2765715608

FWCI: 1.853

Cites: 17

Cited by: 21

Related to: 10